Cancer- and chemotherapy-induced anemia

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 6, 2008, Pages 536-564

  Rodgers III, George M ^a   Becker, Pamela Sue ^b   Bennett, Charles L ^c   Cella, David ^c   Chanan Khan, Asher ^d   Chesney, Carolyn ^e   Cleeland, Charles ^f   Coccia, Peter F ^g   Djulbegovic, Benjamin ^h   Garst, Jennifer L ⁱ   Gilreath, Jeffrey A ^a   Kraut, Eric H ^j   Lin, Weei Chin ^k   Matulonis, Ursula ^l   Millenson, Michael ^m   Reinke, Denise ⁿ   Rosenthal, Joseph ^o   Sabbatini, Paul ^p   Schwartz, Rowena N ^q   Stein, Richard S ^r   Vij, Ravi ^s   more..

^a UNIVERSITY OF UTAH   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g NEBRASKA MEDICAL CENTER   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ DUKE CANCER INSTITUTE   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m FOX CHASE CANCER CENTER   (United States)

ⁿ UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^o Memorial Sloan Kettering Cancer Center ^*

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q JOHNS HOPKINS UNIVERSITY   (United States)

^r UNIVERSITY OF WASHINGTON   (United States)

^s USA

more..

Author keywords

Anemia; Chemotherapy; Darbepoetin; Epoetin; Erythropoietin; Ferric gluconate; Heme iron polypeptide; Hemoglobin; Iron dextran; Iron sucrose; NCCN clinical practice guidelines; Quality of life; Serum ferritin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FLUOROURACIL; HEMOGLOBIN; IFOSFAMIDE; IRON; IRON DEXTRAN; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN; VINCRISTINE;

ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG FATALITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON THERAPY; LOCOREGIONAL FAILURE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; OVARY CANCER; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PURE RED CELL ANEMIA; QUALITY OF LIFE; REVIEW; SCREENING; SEIZURE; THROMBOEMBOLISM; TUMOR GROWTH;

EID: 47549115609     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0042     Document Type: Review

References (91)

1. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007;64:S5-13; quiz S28-30.
2. Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol 2008;26:1022-1024.
3. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202, iii-iv.
4. Moullet I, Salles G, Ketterer N, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9:1109-1115.
5. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
7. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
8. Hill SR, Carless PA, Henry DA, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2002:CD002042.
9. Pawson R, Brunskill S, Murphy MF, et al. Different threshold levels for red blood cell transfusions in patients with haematological malignancy (protocol). The Cochrane Library 2008:10.
10. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 1996;4:82-96.
11. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-986.
12. Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-538.
13. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
14. Jefferies S, Rajan B, Ashley S, et al. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol 1998;48:23-27.
15. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
16. Laurie SA, Jeyabalan N, Nicholas G, et al. Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer. J Thorac Oncol 2006;1:146-151.
17. MacRae R, Shyr Y, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002;64:37-40.
18. Obermair A, Cheuk R, Horwood K, et al. Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: effect on progression-free survival. Int J Gynecol Cancer 2003;13:633-639.
19. Rudat V, Dietz A, Schramm O, et al. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 1999;53:119-125.
20. Cable R, Carlson B, Chambers L, et al. Practice Guidelines for Blood Transfusion: A Compilation from Recent Peer-Reviewed Literature. American Red Cross, 2002.
21. Wiesen AR, Hospenthal DR, Byrd JC, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 1994;121:278-230.
22. Kader AS, Lim JT, Berthelet E, et al. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 2007;30:492-497.
23. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-417.
24. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29:227-234.
25. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006;355:1303-1305.
26. Djulbegovic B. Hematology: Reasoning and Decision Making in Hematology. New York: Churchill Livingstone; 1992.
27. Goodnough LT, Bach RG. Anemia, transfusion, and mortality. N Engl J Med 2001;345:1272-1274.
28. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003;361:161-169.
29. Rao SV, Chiswell K, Sun JL, et al. International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2008;101:25-29.
30. Fatalities reported to the FDA following blood collection and transfusion. Annual summary for fiscal years 2005 and 2006. www.fda.gov/CBER/ blood/fatal0506.htm. Last accessed May 19, 2008.
31. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005;45:254-264.
32. Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007;14:671-676.
33. Hillyer CD, Josephson CD, Blajchmann MA, et al. Bacterial contamination of blood components: risks, strategies, and regulation. Joint ASH and AABB Educational Session in Transfusion Medicine. American Society of Hematology Education Program Book 2003.
34. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004;44:25-29.
35. Parsyan A, Candotti D. Human erythrovirus B19 and blood transfusion - an update. Transfus Med 2007;17:263-278.
36. Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 2003;10:412-418.
37. Popovsky MA. Transfusion Medicine. Bethesda: AABB Press; 1996.
38. Shander A, Popovsky MA. Understanding the consequences of transfusion-related acute lung injury. Chest 2005;128:598S-604S.
39. Yazer MH, Podlosky L, Clarke G, Nahimiak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004;44:10-15.
40. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodys-plastic syndromes. Cancer 2008;112:1089-1095.
41. Vekeman F, Bookhart BK, Duh MS, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply [abstract]. Community Oncology 2008.
42. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
43. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
44. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
45. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-149.
46. Minton O, Stone P, Richardson A, et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 2008:CD006704.
47. Agency for Healthcare Research and Quality. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Available at: http://effectivehealthcare.ahrq.gov/healthInfo.cfm? infotype=rr&ProcessID=4&DocID=35. Accessed May 19, 2008.
48. Phillips C. FDA advisory committee suggests changes to ESA use. NCI Cancer Bulletin, Vol. 4, No. 17. May 15, 2007. Available at: http://www.cancer.gov/ncicancerbulletin/NCl_Cancer_Bulletin_051507/page2.
49. U.S. Food and Drug Administration. Procrit/Epogen Label. Available at: http://www.fda.gov/cder/foi/label/2008/103234s5164lbl.pdf. Accessed May 19, 2008.
50. U.S. Food and Drug Administration. Mircera Label. Available at: http://www.fda.gov/cder/foi/label/2007/125164lbl.pdf. Accessed May 19, 2008.
51. U.S. Food and Drug Administration. Aranesp Label. Available at: http://www.fda.gov/cder/foi/label/2008/103951s5170lbl.pdf.
52. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972.
53. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br] Haematol 2003;122:394-403.
54. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
55. Overgaard J, HoffC, San Hansen H, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 [abstract]. European Journal of Cancer Supplements 2007;5(6):7. Abstract 6LB.
56. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
57. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
58. U.S. Food and Drug Administration. Press release: FDA receives new data on risks of anemia drugs consistent with previous data on tumor growth and death. January 3, 2008. Available at: http://www.fda.gov/bbs/topics/NEWS/2008/ NEW01769.html.
59. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-325.
60. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
61. Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801-831.
62. Erratum in: Clin Ther 2007;29:985-986.
63. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008;26:592-598.
64. Crawford J, Robert F, Perry MC, et al. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2007;2:210-220.
65. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-9386.
66. Heit J A, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
67. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634.
68. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407.
69. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294.
70. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505.
71. Glaspy J, Osterborg A, Ludwig H, et al. Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA) [abstract]. European Journal of Cancer Supplements 2007;5(4):147-147. Abstract 1120.
72. Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005;106:3343-3347.
73. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-1408.
74. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;in press. Epub: 14 May 2008.
75. 2005 Safety Information Alerts. FDA on ESA-associated PRCA. Posted 1 December 2005. Available at: http://www.fda.gov/medwatch/SAFETY/2005/safety05. htm#epoetin.
76. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
77. Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006;22:1403-1413.
78. Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006;24:1079-1089.
79. Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-284.
80. Thames WA, Smith SL, Scheifele AC, et al. Evaluation of the US Oncology Network's tecommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naive patients and patients switched from epoetin alfa. Pharmacotherapy 2004;24:313-323.
81. Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409-417.
82. Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-278.
83. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
84. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
85. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
86. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627-632.
87. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
88. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
89. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004;76:74-78.
90. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.
91. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007;369:1502-1504.